|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||45.43 - 46.49|
|52-week range||32.47 - 62.16|
|Beta (5Y monthly)||1.57|
|PE ratio (TTM)||1.94|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||62.43|
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
AGIO earnings call for the period ending June 30, 2021.